Core Viewpoint - The Hong Kong stock market has seen a rise in discounted placements, with Rongchang Biopharmaceutical (09995.HK) announcing a placement of 19 million shares to raise approximately HKD 796 million, indicating strong market interest despite the company's ongoing losses [1][2][3]. Group 1: Placement Details - Rongchang Biopharmaceutical plans to place up to 19 million H-shares, representing about 10.02% of existing H-shares and 3.49% of total shares as of the announcement date [2]. - The placement price is set at HKD 42.44 per share, reflecting a discount of approximately 9.51% from the closing price on May 21 [2]. - The net proceeds from the placement are expected to be around HKD 796 million, aimed at enhancing research capabilities and business expansion [2]. Group 2: Financial Performance - Despite a revenue increase of 59% to RMB 1.71 billion in 2024, Rongchang Biopharmaceutical continues to operate at a loss, with a net loss of RMB 254 million in Q1 2025, which is a 27% increase in losses year-on-year [6][7]. - The company has only recorded a profit in 2021, primarily due to a licensing agreement with Seattle Genetics, which generated a net profit of RMB 276 million [6][5]. - As of Q1 2025, the company had cash and cash equivalents of RMB 719 million, indicating some liquidity but ongoing pressure on cash flow due to continuous losses [7]. Group 3: Product Pipeline and Market Potential - Rongchang Biopharmaceutical has developed over ten candidate drugs, with seven in clinical development targeting more than twenty indications [3]. - The company’s marketed products, including RC18 and RC48, are undergoing clinical trials for various indications, with RC48 being the first ADC drug in China to receive dual breakthrough therapy designation from both the FDA and the Chinese regulatory authority [4][3]. - The company is focusing on expanding the indications for its core product RC18, which has already received approvals for systemic lupus erythematosus and is expected to gain further approvals in the near future [4]. Group 4: Market Sentiment and Stock Performance - Since the beginning of 2025, Rongchang Biopharmaceutical's stock has surged over 240%, reflecting strong market sentiment and positioning for the placement [8]. - The stock's performance on May 22, where both A and H shares opened low but closed higher, suggests a positive market reaction to the placement announcement [8].

Investment Rating - The report assigns a "Buy" rating to the company, Rongchang Biopharmaceutical (9995 HK) [4][12]. Core Insights - The target price for the company has been raised to HKD 66.00, indicating a potential upside of 40.7% from the current price of HKD 46.90 [1][12]. - The company has initiated an H-share placement to raise approximately HKD 796 million to support pipeline expansion and operations, which is expected to alleviate cash burn pressure significantly [7]. - The revenue for Q1 2025 showed a strong growth of 59.2% year-on-year, driven by increased sales of Taitasip and Vidisizumab [7]. - The report maintains expectations for continued loss reduction in 2025-2026, with a forecasted break-even point in 2027 [7]. Financial Summary - Revenue projections (in million RMB) are as follows: - 2023: 1,076 - 2024: 1,710 - 2025E: 2,365 - 2026E: 3,331 - 2027E: 5,459 - Year-on-year growth rates for revenue are projected at 40.2% for 2023, 58.9% for 2024, 38.3% for 2025, 40.9% for 2026, and 63.9% for 2027 [3][13]. - The net profit (loss) is expected to improve from a loss of RMB 1,511 million in 2023 to a profit of RMB 398 million by 2027 [3][13]. - The report indicates a significant adjustment in the net profit forecast for 2027, increasing by over 60% due to optimistic projections for Taitasip's market performance [7]. Valuation Model - The DCF valuation model estimates the equity value of the company at approximately RMB 33,799 million, translating to a per-share value of HKD 66.00 [9]. - The projected free cash flow is expected to turn positive by 2026, with a forecast of RMB 865 million [9]. Stock Performance - The stock has shown a year-to-date increase of 225.69% [6]. - The 52-week high and low for the stock are HKD 47.00 and HKD 10.62, respectively [6]. Analyst Coverage - The report is authored by analysts from BOCOM International, with contact details provided for further inquiries [7].

港股生物医药板块回调走弱，泰格医药(03347.HK)跌近3%，荣昌生物(09995.HK)跌超2%，百济神州 (06160.HK)、药明康德(02359.HK)等跟跌。 ...

Group 1 - The company, Rongchang Biopharma (09995.HK), has entered into a placement agreement with Morgan Stanley and Huatai International to issue 19 million new H-shares at a placement price of HKD 42.44, which represents a discount of approximately 9.51% compared to the closing price of HKD 46.90 on May 21 [1] - The placement shares will account for about 10.02% of the existing issued H-shares and approximately 3.49% of the total issued shares as of the announcement date [1] - Assuming no other changes in the issued share capital, the placement shares will represent about 9.11% of the enlarged issued H-shares and approximately 3.37% of the total issued shares after the placement [1] Group 2 - The total estimated proceeds from the placement are approximately HKD 806 million, with net proceeds expected to be around HKD 796 million after deducting commissions and estimated expenses [2] - The company plans to use the net proceeds for the expansion of its core product, RC18, into key indications such as myasthenia gravis, membranous nephropathy, and for general corporate purposes [2]

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2025-025 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 关于根据一般授权发行 H 股的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 释义 | 除非文义另有所指外，下列词汇具有以下涵义： | | --- | | A股 | 指 | 本公司股本中每股面值人民币1.00元之人民币普 | | --- | --- | --- | | | | 通股，于上海证券交易所科创板上市 | | 年度股东大会 | 指 | 本公司于2024年6月28日举行的年度股东大会 | | 联系人 | 指 | 具有《上市规则》所赋予的涵义 | | 董事会 | 指 | 本公司董事会 | | | | 持牌银行于香港一般开放营业及联交所于香港一 | | 营业日 | 指 | 般开放买卖证券的任何日子（周六、周日及香港公 | | | | 众假期除外） | | | | 中华人民共和国（仅就本公告而言，不包括香 ...

Market Overview - A-shares experienced a broad rally on May 20, with overall market activity increasing and trading volume expanding, as both A-shares and Hong Kong stocks rose over 1% [1] - The three major A-share indices saw significant gains, with the Shanghai Composite Index closing up 0.38% at 3380.48 points, the Shenzhen Component Index up 0.77% at 10249.17 points, and the ChiNext Index up 0.77% at 2048.46 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 12.114 trillion yuan, an increase of 923 billion yuan compared to the previous day [1] Pet Economy Concept - The pet economy concept surged, with over 3800 stocks in the market showing gains, including Tianyuan Pet (301335) hitting a 20% limit up and reaching a new high, and Lusi Co. (832419) also hitting a limit up [2][4] - The pet market has been maintaining high growth rates, benefiting from domestic brand replacement effects and continuous improvements in product and brand strength, leading to significant year-on-year sales increases [4][6] - Analysts expect the pet sector's performance to continue reaching new highs in 2024 and the first quarter of 2025, driven by stable overseas orders and the growth of domestic pet food brands [6] Innovative Drug Concept - The innovative drug concept saw a strong performance, with significant gains in stocks such as Sangfor Biopharma (01530) which rose over 32%, and other companies like Rongchang Biopharma (688331) and Yifang Biopharma (688382) also experiencing substantial increases [8][10] - Sangfor Biopharma announced a collaboration with Pfizer for the exclusive global development rights of a dual-target antibody, SSGJ-707, which has shown promising results in clinical trials for non-small cell lung cancer [8][10] - The innovative drug sector is expected to benefit from potential changes in international drug pricing strategies, which may position China as a low-cost research and production center [13] Shipping Concept - The shipping sector experienced a significant pullback, with stocks like Guohang Ocean (833171) dropping nearly 18%, and several others hitting the daily limit down [15][16] - Despite the recent downturn, companies like Lianyungang (601008) and Ningbo Ocean (601022) have reassured investors that their operations remain normal and that there are no significant changes in industry policies [17]

Market Overview - A-shares experienced a broad rally on May 20, with the Shanghai Composite Index closing up 0.38% at 3380.48 points, the Shenzhen Component up 0.77% at 10249.17 points, and the ChiNext Index up 0.77% at 2048.46 points. The total trading volume across the three exchanges reached 121.14 billion yuan, an increase of 9.23 billion yuan from the previous day [1][2]. Pet Economy - The pet economy concept saw significant gains, with Tianyuan Pet (301335) hitting a 20% limit up and reaching a new high. Lusi Co. (832419) also hit a limit up, marking a new high. Other companies in this sector, such as Bei Yin Mei (002570) and Yi Yi Co. (001206), also experienced limit up [4][5][6]. - Analysts noted that the pet market has maintained high growth rates in recent years, benefiting from domestic brand replacement effects and improvements in product and brand strength. This has led to significant year-on-year sales growth and price increases for domestic brands [7]. Innovative Drug Sector - The innovative drug sector showed strong performance, with Yipin Hong (300723) and San Sheng Guo Jian (688336) both hitting the 20% limit up. Other companies like Rongchang Bio (688331) and Yifang Bio (688382) saw increases of approximately 16% [8][9]. - San Sheng Guo Jian announced a collaboration with Pfizer for the exclusive global development and commercialization rights of a dual-target antibody, SSGJ-707, which has shown promising results in clinical trials for non-small cell lung cancer [10][11]. Shipping Sector - The shipping sector experienced a significant pullback, with companies like Guo Hang Yuan Yang (833171) dropping nearly 18%, and others such as Fenghuang Shipping (000520) and Lianyungang (601008) hitting their daily limit down [16][17]. - Lianyungang, which had seen five consecutive limit up days, reported a 48.01% year-on-year decline in net profit for the first quarter of 2025, raising concerns among investors [18][19].

Group 1 - The Hong Kong Innovation Drug Index (987018) has seen a strong increase of 4.01% as of May 20, 2025, with notable gains from companies such as 3SBio (01530) up 30.90%, Zai Lab (09688) up 6.59%, and Rongchang Bio (09995) up 5.69% [1] - The Hong Kong Innovation Drug ETF (159567) opened high and rose by 3.66%, marking its third consecutive increase, with the latest price reported at 1.27 yuan [1] - Over the past week, the Hong Kong Innovation Drug ETF has accumulated a rise of 5.31%, with a turnover rate of 7.38% and a transaction volume of 1.09 billion yuan [1] Group 2 - Donghai Securities reported that Trump's executive order requiring pharmaceutical companies to sell drugs in the U.S. at "most favored nation" prices may face judicial challenges and execution details, leading to short-term uncertainty [2] - Long-term implications suggest that breaking the current international drug pricing gradient could prompt global pharmaceutical companies to adjust pricing strategies, with China's innovative drugs benefiting from low R&D costs and high efficiency [2] - The report highlights potential investment opportunities in segments such as innovative drug chains, medical devices, traditional Chinese medicine, medical services, and chain pharmacies [2]

Investment Rating - The report assigns a rating of "Buy" with a target price of HKD 45.00 for Rongchang Biologics (9995 HK) [4][5]. Core Insights - The approval of the new indication for Vidisicimab in treating HER2-positive metastatic breast cancer with liver metastasis is expected to boost product sales significantly [1]. - The company has made progress in clinical trials for new indications, including a Phase III study for Vidisicimab in combination with Toripalimab for advanced or metastatic urothelial carcinoma [2]. - The Q1 2025 financial results exceeded expectations, with revenue increasing by 59.1% year-on-year to RMB 530 million, and a reduction in net loss by 27.2% to RMB 250 million [3]. Financial Projections - Revenue forecasts for 2025 and 2026 have been raised by 3.2% and 4.8%, respectively, while net loss projections have been lowered by 5.2% and 13.5% [4]. - The company anticipates total revenue to reach RMB 1,076 million in 2023, growing to RMB 3,798 million by 2027, reflecting a compound annual growth rate of 40.2% from 2023 to 2024 [11]. - The projected net loss is expected to decrease from RMB 1,511 million in 2023 to a profit of RMB 29 million by 2027 [11]. Stock Information - The current closing price is HKD 39.20, with a market capitalization of HKD 26,972.99 million [5]. - The stock has a 52-week price range of HKD 10.2 to HKD 46.90 [5].

Group 1 - The stock market showed strength on May 14, with both the ChiNext Index and Shanghai Composite Index rising over 1%, while the Hong Kong Hang Seng Index increased by 2% and the Hang Seng Tech Index rose by over 2% [1] - Popular ETFs such as the Biopharmaceutical ETF (159859) and the Innovative Drug Hong Kong-Shanghai ETF (517380) turned positive in the afternoon, with the Innovative Drug ETF up 0.35% and key components like China National Pharmaceutical Group and Hengrui Medicine rising over 3% [1] - The Biopharmaceutical ETF tracks the National Biopharmaceutical Index, which includes the top 30 stocks in the biopharmaceutical sector based on market capitalization and liquidity, reflecting the overall performance of the industry [1] Group 2 - The 36th Pharmaceutical Economic Information Conference was held in Guangzhou from May 12 to 14, focusing on drug regulation policies, industry trends, and high-quality development in the pharmaceutical sector [2] - According to Founder Securities, the pharmaceutical and biotechnology sector's Q1 2025 financial reports showed stable revenue and profit performance, with notable improvements in certain sub-sectors, particularly in pharmaceutical R&D outsourcing, which achieved over 10% growth in both revenue and profit [2] - The market sentiment towards the pharmaceutical industry has improved, with a noticeable increase in equity fund allocations since Q1 2024, driven by a systematic valuation increase in the innovative drug sector [2]